COMMUNIQUÉS West-GlobeNewswire

-
Teligent, Inc. Receives Notification of Deficiency From NASDAQ Related to the Delayed Filing of Form 10-Q
16/11/2018 -
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
16/11/2018 -
CareDx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/11/2018 -
Ziopharm Oncology Provides Controlled IL-12 Update with Positive Data from Phase 1 Trial Presented at Annual Meeting of the Society for Neuro-Oncology
16/11/2018 -
Golden Leaf Closes C$7.9 million Private Placement of Unsecured Convertible Subordinated Debenture Units
16/11/2018 -
Letter to Shareholders to accompany recent proxy filing
16/11/2018 -
Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe
16/11/2018 -
New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System
16/11/2018 -
ATW Tech Provides Additional Information Regarding Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group
16/11/2018 -
ATW Tech fournit de l’information additionnelle sur la signature de la lettre d’intention pour l’acquisition majeure du Groupe Greywolf Entertainement
16/11/2018 -
Lifestyle Brand Weekend Unlimited Expanding Into Key US, Foreign Markets -- CFN Media
16/11/2018 -
Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference
16/11/2018 -
Aurora Spine Announces Exclusive Patent License Agreement for MIS SI Joint Product
16/11/2018 -
Dragon Jade Announces Filing of Registration Statement for Proposed Registered Offering
16/11/2018 -
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
16/11/2018 -
Progressive Care Inc. Announces Record-Breaking October 2018
16/11/2018 -
Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
16/11/2018 -
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
16/11/2018 -
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
16/11/2018
Pages